GENB (Generate Biomedicines) ROCE %: -65.23% (As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines ROCE %?

Generate Biomedicines GENB +2.18% 6 ROCE % is -65.23% as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Generate Biomedicines's annualized ROCE % for the quarter that ended in Dec. 2025 was -65.23%.

Generate Biomedicines  (NAS:GENB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Generate Biomedicines ROCE % Related Terms

Generate Biomedicines ROCE % Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines ROCE % Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
ROCE %
-41.48 -65.23

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
ROCE % -41.48 -65.23
GENB
6GF Score
Generate Biomedicines Inc GENB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines ROCE % Calculation

Generate Biomedicines's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-221.666/( ( (518.259 - 86.626) + (330.182 - 82.203) )/ 2 )
=-221.666/( (431.633+247.979)/ 2 )
=-221.666/339.806
=-65.23 %

Generate Biomedicines's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Dec. 2024 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Dec. 2024 )(Q: Dec. 2025 )
=-221.666/( ( (518.259 - 86.626) + (330.182 - 82.203) )/ 2 )
=-221.666/( ( 431.633 + 247.979 )/ 2 )
=-221.666/339.806
=-65.23 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -65.23% mean?
Generate Biomedicines (GENB) has a ROCE % of -65.23% as of Dec. 2025.
Is Generate Biomedicines' ROCE % too high?
Generate Biomedicines' current ROCE % is -65.23%. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' ROCE % compare to PVLA and SLBT?
Generate Biomedicines' ROCE % of -65.23% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Generate Biomedicines's current ROCE % is -65.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current ROCE % of -65.23%. The current ROCE % is -65.23%. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current ROCE % is -65.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price